和铂医药-B(02142)早盘逆市走强,股价上涨14.94%,现报2.77港元,成交额1806.94万港元。
和铂医药宣布,与科伦博泰就HBM9378/SKB378与Windward Bio AG(以下简称“Windward Bio”)签订许可协议。HBM9378/SKB378是一款由和铂医药与科伦博泰联合开发的靶向胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体。根据协议,Windward Bio获得HBM9378/SKB378在全球范围内(不包括大中华区以及部分东南亚及西亚国家)进行研究、开发、生产和商业化的独家授权。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.